Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the small-cap stocks that are on fire right now. On April 16, Spyre Therapeutics successfully closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final total reflects the full exercise of the underwriters’ option to purchase an additional 975,000 shares, bringing the total number of shares of common stock sold to 7,475,000 at a public offering price of $62.00 per share.

The company plans to use these funds to further its development of long-acting antibodies and combination therapies targeting inflammatory bowel disease/IBD and rheumatic conditions. The offering was managed by a consortium of major financial institutions, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities acting as joint book-running managers. LifeSci Capital LLC served as a passive bookrunner.

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

15 States with the Best Healthcare in the US

The transaction was conducted under a registration statement that became effective in February, with the final prospectus supplement filed concurrently with the closing. This substantial capital infusion strengthens Spyre Therapeutics Inc.’s (NASDAQ:SYRE) financial position as it seeks to redefine standards of care for chronic inflammatory diseases.

Spyre Therapeutics Inc. (NASDAQ:SYRE) is a US biotechnology company focused on developing medicines for people living with inflammatory bowel disease and rheumatic diseases. It develops advanced antibodies engineered for prolonged activity and formulated for delivery as monotherapies.

While we acknowledge the risk and potential of SYRE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYRE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.